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Abstract
Background: Multifactor Dimensionality Reduction (MDR) is a novel method developed to detect
gene-gene interactions in case-control association analysis by exhaustively searching multi-locus
combinations. While the end-goal of analysis is hypothesis generation, significance testing is
employed to indicate statistical interest in a resulting model. Because the underlying distribution
for the null hypothesis of no association is unknown, non-parametric permutation testing is used.
Lately, there has been more emphasis on selecting all statistically significant models at the end of
MDR analysis in order to avoid missing a true signal. This approach opens up questions about the
permutation testing procedure. Traditionally omnibus permutation testing is used, where one
permutation distribution is generated for all models. An alternative is n-locus permutation testing,
where a separate distribution is created for each n-level of interaction tested.
Findings: In this study, we show that the false positive rate for the MDR method is at or below a
selected alpha level, and demonstrate the conservative nature of omnibus testing. We compare the
power and false positive rates of both permutation approaches and find omnibus permutation
testing optimal for preserving power while protecting against false positives.
Conclusion: Omnibus permutation testing should be used with the MDR method.
Background
One of the main goals of genetic epidemiology is the iden-
tification and characterization of polymorphisms that
present an increased risk of disease. It is increasingly
assumed that complex diseases are the result of a myriad
of genetic and environmental risk factors [1,2]. This com-
plex etiology limits the utility of traditional, parametric
statistical approaches in genetic association studies [3,4].
The ubiquitous nature of gene-gene and gene-environ-
ment interactions [1,5,6] has inspired the development
the novel statistical approaches designed to detect epista-
sis [7-9].
Multifactor Dimensionality Reduction (MDR) is one such
method [10]. MDR was designed to detect interactions in
categorical independent variables and a dichotomous
dependent variable (i.e. case/control status or drug treat-
ment response/non-response). MDR performs an exhaus-
tive search of all possible single-locus through n-locus
interactions (as computationally feasible) to evaluate all
possible high/low risk models of disease. MDR selects a
single model as optimal for each n-locus interaction as a
result of these evaluations. Permutation testing (PT) is
used to determine the significance of these models. MDR
is nonparametric and model-free, so no hypotheses con-
cerning the value of any statistical parameter nor any
genetic inheritance model are made [10]. MDR has suc-
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cessfully identified interactive effects in simulated data as
well as real data applications in diseases such as hyperten-
sion [3,11,12], cancer [10,13,14], and atrial fibrillation
[15,16].
The end-goal of an MDR analysis is ultimately hypothesis
generation (or refinement within candidate gene strate-
gies) [17]. Hypothesis testing is used within the MDR
analysis framework to determine whether resulting mod-
els are significantly different than expected by chance. Sig-
nificance of a model is intended to indicate an interesting
model that should be followed up in replication cohorts
or functional studies. In recent work, there has been more
emphasis on selecting all statistically significant models
[17] in order to avoid missing a true signal (false nega-
tives) in exchange for risking the selection of a few false
positives. This generation of multiple hypotheses opens
up questions about the PT procedure used to ascribe sig-
nificance to this end set of models.
PT is a commonly used non-parametric statistical proce-
dure that involves re-sampling the data without replace-
ment to actually construct the distribution of the test
statistic under the null hypothesis rather than make spe-
cific distributional assumptions. If the value of the test sta-
tistic based on the original samples is extreme relative to
this distribution (i.e. if it falls far into the tail of the distri-
bution), then the null hypothesis is rejected [18]. Validity
of PT relies only on the property of exchangeability under
the null hypothesis – that the joint distribution of the data
samples must remain invariant to permutations of the
data subscripts. Thus, permutation tests maintain a wide
applicability under a much broader range of data and
research conditions than most parametric tests [19]. In
addition, PT requires minimal assumptions about the
data being examined, yet often has power equal to, or
even greater than, parametric counterparts that require
stronger, and sometimes untenable data assumptions
[20]. Unlike many parametric and other nonparametric
tests, the results of permutation tests (the p-values) are
unbiased [18]. The chief drawback of this method is that
it is computationally expensive, but the easy availability
of fast computing has made this a practical approach even
for large datasets.
MDR implements PT to statistically test to the best
model(s) [21]. Typically, omnibus PT is used, where a sin-
gle null distribution is generated from the best model of
each of at least one thousand randomized datasets. With
a focus on selecting all potentially interesting models
from the final MDR set, this omnibus method may be too
conservative. n-locus PT is an alternative, where a separate
null distribution is created for each n-level of interaction.
So if single-locus through five-way interactions were eval-
uated in an original MDR analysis, a separate distribution
would be created for the single-locus model, for the two-
locus model, etc (for a total of five null distributions).
Currently, we compare the significance cut-offs, power,
and false positive rates of omnibus PT and n-locus PT
implemented in MDR for a wide range of disease models.
We also examine the overall false positive rate of the MDR
method using both types of PT. As the MDR method gains
acceptance and is increasingly used in the genetics com-
munity, it is important that users understand how to
properly apply PT.
Multifactor Dimensionality Reduction (MDR)
Figure 1 (adapted from [10]) outlines the MDR proce-
dure. Details of the algorithm and of the alternative PT
strategies implemented in the current study can be found
in Additional file 1.
Data Simulations and Analysis
Simulated datasets that exhibit gene-gene interactions
were generated for the purpose of evaluating the power
and false positives of MDR using either omnibus or n-
locus PT. Multiple disease models, as well as null data
with no disease model, were generated with varying allele
frequencies, heritability, and number of interacting func-
tional polymorphisms. Details of the simulations and
analysis are found in Additional file 1.
Results
Null data was used to check the false positive rates of both
permutation-testing strategies in the absence of any signal
from the data. Best models were chosen for each dataset
based on low prediction error and high cross-validation
consistency and compared to the appropriate permuta-
tion distribution. Table 1 shows the false positive rate for
each permutation distribution, with alpha = 0.05, where
the false positive rate is estimated as the number of mod-
els that were declared significant by PT out of the 100
datasets analyzed. These results demonstrate that the false
positive rate is nominal for each permutation distribution
– the error rate is at or below the selected alpha level.
Both omnibus and n-locus permutation distributions
were created for each model, and the highest prediction
error that would be ascribed statistical significance at the
alpha = 0.05 level was recorded (cut-offs for significance).
Table 2 lists these cut-offs for omnibus testing and each
possible n-locus distribution. For each model, the most
conservative cut-off is highlighted with bold font. These
results demonstrate that omnibus PT consistently pro-
vides the most conservative PT cut-offs, as its cut-off pre-
diction errors are the lowest. There is also a general trend
within the n-level PT distributions that as the level of n
increases, so does the corresponding cut-off value. ThisBMC Research Notes 2008, 1:139 http://www.biomedcentral.com/1756-0500/1/139
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demonstrates that the n-locus PT becomes more liberal as
the level of dimensionality increases.
While the anti-conservative nature of n-locus PT could
potentially increase power, it is undesirable if that results
in an increased false positive rate. To evaluate this, we
investigated the false positive rate of each n-locus permu-
tation distribution for each model. MDR analysis was per-
formed on each dataset for all single-locus through five-
locus combinations, and a best model was chosen for
each level of interaction. For each dataset, the best model
for each level of interaction was compared to the appro-
priate n-locus permutation distribution to estimate the
false positive rate where a false positive result was any
model that is not correct (may contain only incorrect loci
or correct loci with additional false positive loci) and was
found statistically significant according to the appropriate
permutation distribution. Summarized in Table 3, using
this definition of power, the false positive rate is extremely
high for any n-level interaction above the true genetic
model. For example, for the two-locus interaction model
with 0.2 minor allele frequency and 3% heritability, all
three, four, and five locus models were statistically signif-
icant.
To better understand this trend, we estimated power for
each model as the number of times all functional loci
(with or without additional/false positive loci) were iden-
tified within the best model for any n-level interaction and
was called significant according to the corresponding per-
mutation distribution out of the 100 simulated datasets
per model. Table 4 summarizes these results. These results
suggest that the false positive rates shown in Table 3 may
be driven by the inclusion of functional loci in higher-
level interactions. This trend was seen for all models, but
is especially apparent in higher heritability models. This
suggests, especially in the case of a relatively strong signal
An overview of the MDR method Figure 1
An overview of the MDR method. Steps correspond to those described in the supplemental information.
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Table 1: False positive rate for null data
Permutation Distribution False Positive Rate (%)
l Locus 2 Locus 3 Locus 4 Locus 5 Locus Omnibus
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from the data, that even containing the correct loci within
the model is enough to drive it to statistical significance
according to a more liberal PT procedure. This is a highly
likely explanation, especially considering the nominal
false positive rates demonstrated for null data (Table 1).
Table 4 shows that the power of MDR is relatively high in
lower order models, especially at the n-locus level of anal-
ysis. Interpretation of an MDR analysis is complicated,
however, when using n-locus PT by the high level of false
positives. Even though the functional loci are included in
the significant models, choosing the correct order of inter-
action is difficult when n-locus PT is used for each level of
interaction.
Understanding that omnibus PT is the more conservative
option, we investigated its impact on both the overall
power and false positive rates of the MDR method. Table
5 summarizes these results for each disease model. First,
we wanted to compare the power of MDR to detect the
correct model as the final model (through minimization
of prediction error and maximization of cross validation
consistency) without considering statistical significance.
Power was estimated as the number of times the func-
tional/disease associate loci were chosen as the best
Table 2: Permutation testing significance cut-offs.
Epistasis Model Permutation Distribution Cut-Off Prediction Error (%)
Number of Functional Loci Minor Allele Frequency Heritability 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus Omnibus
2 0.2 3% 43.5 43.71 44.48 43.42 44.19 43.5
2 0.2 2% 43 42.5 43.83 43.84 43.82 41.25
2 0.2 1.5% 43.75 42.85 43.73 43.64 43.45 42.5
2 0.2 1% 43.5 42.75 44.12 45.05 44.24 41.84
2 0.2 0.5% 43.5 43.25 43.19 42.68 43.68 40.75
2 0.4 3% 42.75 43.75 44.12 43.15 44.22 41.02
2 0.4 2% 44.5 44.75 45 44.55 43.77 42.25
2 0.4 1.5% 44.25 43.5 42.46 42.34 43.62 40.25
2 0.4 1% 43 43.75 42.5 44.53 44.28 40.25
2 0.4 0.5% 43.5 43.25 43.31 44.2 43.2 41.5
3 0.2 3% 43.25 43.36 43.94 43.92 43.96 42.75
3 0.2 2% 43.25 42.5 44.09 44.14 45.71 41.5
3 0.2 1.5% 42.75 43.75 46.08 45.34 44.2 42.25
3 0.2 1% 42.75 43.75 43.85 43.47 44.36 42.5
3 0.2 0.5% 43.5 43.25 42.79 42.9 43.28 42.5
3 0.4 3% 43.25 43 45.5 45.74 45.15 42.5
3 0.4 2% 42.5 45 43.75 43.14 44.2 42.25
3 0.4 1.5% 42.75 45.25 44.22 45.56 43.74 42.5
3 0.4 1% 44.5 43 44.25 44.79 42.89 41.5
3 0.4 0.5% 43.25 44.5 43.86 44.92 44.5 42.09
4 0.2 3% 44.5 41.5 43.86 43.39 44.37 41.5
4 0.2 2% 43 42.6 43.29 45.76 45.13 42.5
4 0.2 1.5% 42.5 42.85 43.4 42.54 43.02 40.59
4 0.2 1% 43.75 43.1 43.16 44.07 44.15 41.22
4 0.2 0.5% 44 44 43.56 46.65 43.85 42.97
4 0.4 3% 44.5 43.25 44.49 44.03 45.2 41.07
4 0.4 2% 42.25 43.5 43.84 43.66 44.18 40.75
4 0.4 1.5% 42.25 43.5 45.25 44.08 42.64 41.49
40 . 4 1 % 41.5 45 43.25 44.05 44.2 41.5
4 0.4 0.5% 41.75 44 44.85 44.4 43.41 41
5 0.2 3% 44.25 42.25 44.85 43.75 45.43 41
5 0.2 2% 42.75 43.5 44.63 45.32 46.04 41.05
5 0.2 1.5% 43.25 41.5 43.57 44.88 44.35 40.75
5 0.2 1% 43.75 44.62 45.1 43.54 45.06 41.71
5 0.2 0.5% 44 43.62 44.25 44.05 44.57 40.08
5 0.4 3% 43.5 42.5 43.75 43.99 43.11 41.25
5 0.4 2% 43.25 44 44.5 44.51 44.23 40.78
5 0.4 1.5% 45 43.5 44.97 44.96 43.83 42.5
5 0.4 1% 42.25 42.5 44.75 45.32 43.43 40.75
5 0.4 0.5% 44 43.25 43.5 45.14 45.01 39.75BMC Research Notes 2008, 1:139 http://www.biomedcentral.com/1756-0500/1/139
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model across the 100 replicates, with no false positive loci
included in the model. By defining power in this context
(with no PT), this estimate represents the least conserva-
tive estimate. These results are equivalent to the least con-
servative cut-off possible with n-locus PT. By defining
power in this way, by using any significance testing the
power cannot possibly be higher – all results that count
towards "power" under this definition can only be
changed to non-significant by using any significance test-
ing. Results are summarized in the column of Table 5
labeled "Power Without Permutation Testing". This is
then compared to the power of MDR to not only find the
correct model, but to also ascribe statistical significance to
that model through omnibus PT. Results of this evalua-
tion are presented in the column of Table 5 labeled
"Power With Permutation Testing". Comparing the power
with and without permutation demonstrates the results
are similar. Omnibus PT does not severely limit the power
of the method.
Finally, we evaluated the impact of omnibus PT on the
false positive rate. The false positive rate was estimated for
each model as the number of incorrect final models that
were statistically significant using omnibus PT. This calcu-
lation included significance testing at each level of inter-
action – not just a single test for one overall best model.
Table 3: False positive rates for n-locus permutation distributions.
Epistasis Model N-Locus Permutation Distribution False Positive Rate (%)
Number of Functional Loci Minor Allele Frequency Heritability 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus
2 0.2 3% 4 0 100 100 100
2 0.2 2% 2 0 84 76 62
2 0.2 1.5% 3 0 89 78 57
2 0.2 1% 3 1 50 55 33
2 0.2 0.5% 3 1 17 5 6
2 0.4 3% 4 0 95 89 76
2 0.4 2% 7 0 96 93 69
2 0.4 1.5% 7 0 82 57 45
2 0.4 1% 4 1 31 24 19
20 . 4 0 . 5 % 6 3 6 1 3 8
3 0.2 3% 3 5 0 100 100
3 0 . 2 2 % 23 60 1 0 0 9 4
3 0.2 1.5% 2 65 33 67 48
3 0.2 1% 4 40 22 22 22
3 0 . 2 0 . 5 % 21133
3 0 . 4 3 % 61 00 1 0 0 9 3
3 0 . 4 2 % 54 625 7 4 6
3 0.4 1.5% 3 43 4 61 26
3 0.4 1% 11 12 13 17 4
3 0 . 4 0 . 5 %51 051 46
40 . 2 3 % 9 4 6 8 5 0 9 5
40 . 2 2 % 4 3 1 6 4 4 9 0
4 0.2 1.5% 1 18 26 11 20
4 0 . 2 1 %6568 1 8
4 0.2 0.5% 6 9 8 23 11
40 . 4 3 % 6 1 6 6 3 7 7 7
4 0.4 2% 0 7 24 3 23
4 0.4 1.5% 4 5 15 3 5
4 0 . 4 1 % 11 47 41 2
4 0 . 4 0 . 5 %21 19 9 3
5 0.2 3% 4 21 51 64 21
5 0.2 2% 1 10 27 64 23
5 0 . 2 1 . 5 % 11669
5 0.2 1% 7 14 20 18 13
5 0 . 2 0 . 5 % 32335
5 0.4 3% 7 5 11 16 6
50 . 4 2 % 1 6 6 1 2 7
5 0 . 4 1 . 5 % 73785
5 0.4 1% 0 2 10 10 6
5 0.4 0.5% 10 6 3 4 6BMC Research Notes 2008, 1:139 http://www.biomedcentral.com/1756-0500/1/139
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As Table 5 shows, the false positive rates are near the
expected 5% level.
From the results presented in Table 5, we conclude that
omnibus PT controls for false positives while preserving
power.
Conclusion
In this study we confirmed that the overall false positive
rate of MDR is as expected according to the selected alpha
level. Additionally, we demonstrated the conservative
nature of omnibus testing in comparison to an n-locus
strategy.
We also demonstrated that omnibus PT is preferred to n-
locus since it controls false positives without limiting
power. While MDR has high power using either permuta-
tion-testing scenario, final model selection is complicated
by the more liberal n-locus strategy of PT. While the final
goal of MDR is hypothesis generation, and the user may
prefer the risk of false positives to the risk of missing a true
signal, it is recommended that significance levels be
assigned to one or more models from the final set using
the omnibus permutation distribution, and not using cor-
responding n-locus tests.
Table 4: Power (with or without additional loci) for n-locus permutation distributions.
Epistasis Model N-Locus Permutation Distribution Power (%)
Number of Functional Loci Minor Allele Frequency Heritability 1 Locus 2 Locus 3 Locus 4 Locus 5 Locus
2 0.2 3% 0 100 100 100 100
2 0.2 2% 0 100 95 92 89
2 0.2 1.5% 0 91 97 92 89
2 0 . 2 1 % 0 5 58 08 57 4
2 0.2 0.5% 0 18 45 35 41
2 0.4 3% 0 100 97 93 86
2 0.4 2% 0 100 100 100 92
2 0.4 1.5% 0 100 100 92 80
2 0 . 4 1 % 0 6 77 36 45 1
2 0.4 0.5% 0 12 40 30 28
3 0.2 3% 0 0 100 100 100
3 0.2 2% 0 0 100 100 100
3 0.2 1.5% 0 0 46 58 55
3 0.2 1% 0 0 2 24 39
3 0.2 0.5% 0 0 1 16 20
3 0.4 3% 0 0 100 100 100
3 0.4 2% 0 0 70 86 67
3 0.4 1.5% 0 0 65 65 39
3 0.4 1% 0 0 10 32 15
3 0.4 0.5% 0 0 2 12 8
4 0 . 2 3 % 000 1 0 0 1 0
4 0.2 2% 0 0 0 91 10
4 0.2 1.5% 0 0 0 15 4
4 0 . 2 1 % 00094
4 0 . 2 0 . 5 %00014
4 0.4 3% 0 0 0 82 11
4 0.4 2% 0 0 0 29 6
4 0.4 1.5% 0 0 0 12 4
4 0 . 4 1 % 00031
4 0 . 4 0 . 5 %00010
5 0 . 2 3 % 0000 6 7
5 0 . 2 2 % 0000 4 9
5 0 . 2 1 . 5 %00000
5 0 . 2 1 % 0000 2 2
5 0 . 2 0 . 5 %00000
5 0 . 4 3 % 0000 1 8
5 0 . 4 2 % 00002
5 0 . 4 1 . 5 %00001
5 0 . 4 1 % 00001
5 0 . 4 0 . 5 %00001BMC Research Notes 2008, 1:139 http://www.biomedcentral.com/1756-0500/1/139
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While these results are most immediately applicable to
genetic epidemiologists using MDR, they may generalize
to any computational method that involves PT. Addition-
ally, as MDR gains acceptance and becomes more widely
used, it is important that the consequences of alternative
permutation strategies should be explored and under-
stood. Recent work is also implementing alternative
hypothesis testing strategies for MDR that are computa-
tionally feasible for extremely large-scale datasets [22].
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MDR: Multifactor Dimensionality Reduction; PT: Permu-
tation testing.
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Table 5: Power of MDR with and without omnibus permutation testing and false positive rate with permutation testing.
Epistasis Model
Number of Functional 
Loci
Minor Allele Frequency Heritability Power (%) Without 
Permutation Testing
Power (%) With 
Permutation Testing
False Positive Rate (%) 
With Permutation 
Testing
20 . 2 3 %
2 0.2 2% 90 88 0
2 0.2 1.5% 94 91 1
2 0.2 1% 70 56 6
2 0.2 0.5% 18 14 4
2 0.4 3% 93 93 2
2 0.4 2% 93 92 5
2 0.4 1.5% 95 91 1
2 0.4 1% 85 71 6
2 0.4 0.5% 25 11 0
3 0.2 3% 69 69 2
3 0.2 2% 85 85 2
3 0.2 1.5% 20 18 5
3 0.2 1% 6 2 6
3 0.2 0.5% 6 2 4
3 0.4 3% 89 89 1
3 0.4 2% 55 54 3
3 0.4 1.5% 40 34 2
3 0.4 1% 6 4 2
3 0.4 0.5% 3 0 1
4 0.2 3% 68 68 4
4 0.2 2% 59 57 8
4 0.2 1.5% 11 10 4
4 0.2 1% 10 9 2
4 0.2 0.5% 1 0 1
4 0.4 3% 60 52 1
4 0.4 2% 36 25 5
4 0.4 1.5% 4 4 7
4 0.4 1% 3 2 6
4 0.4 0.5% 0 0 3
5 0.2 3% 35 35 3
5 0.2 2% 3 3 3
5 0.2 1.5% 1 0 2
5 0.2 1% 20 11 4
5 0.2 0.5% 0 0 1
5 0.4 3% 15 10 0
5 0.4 2% 3 2 6
5 0.4 1.5% 0 0 9
5 0.4 1% 0 0 0
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